- Axsome Therapeutics settles a patent dispute with Hetero Labs over Sunosi, paving the way for future generic competition.
- Analysts forecast significant upside potential for AXSM, with an average target price of $176.53.
- GuruFocus estimates a potential 137.59% upside, based on their GF Value calculation for the stock.
Axsome Therapeutics (AXSM, Financial) has successfully concluded a patent dispute with Hetero Labs relating to a generic version of its sleep disorder drug, Sunosi. This amicable resolution resolves the litigation and opens the door for Hetero to commercialize its version by 2040, subject to regulatory green lights. The agreement is currently under the final review process by U.S. authorities.
Wall Street Analysts' Forecast: Bright Prospects for Axsome Therapeutics
Seventeen analysts have put forth one-year price targets for Axsome Therapeutics Inc. (AXSM, Financial), with an average target of $176.53. These forecasts vary, with the highest estimate at $210.00 and the lowest at $146.00. This average target indicates a potential upside of 68.01% from the current stock price of $105.07. Investors can explore more detailed projections on the Axsome Therapeutics Inc (AXSM) Forecast page.
The consensus recommendation from 18 brokerage firms places Axsome Therapeutics Inc. (AXSM, Financial) in an "Outperform" category, with an average brokerage recommendation of 1.7. This rating scale ranges from 1 to 5, where 1 represents a Strong Buy, and 5 depicts a Sell.
GuruFocus Metrics: Evaluating the GF Value of AXSM
According to GuruFocus estimates, the anticipated GF Value for Axsome Therapeutics Inc. (AXSM, Financial) over the next year is $249.64. This suggests an impressive potential gain of 137.59% from the current price of $105.07. The GF Value represents GuruFocus' assessment of the stock's fair value, calculated based on historical trading multiples, past business growth, and future business performance estimates. Investors can find more insightful data on the Axsome Therapeutics Inc (AXSM) Summary page.
